IBRN Holdings — iShares Neuroscience and Healthcare ETF
All 84 reported holdings of iShares Neuroscience and Healthcare ETF (IBRN) by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets | Value (USD) |
|---|---|---|
| BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares | 8.57% | $443.51K |
| Xenon Pharmaceuticals Inc | 4.79% | $247.64K |
| Axsome Therapeutics, Inc. | 4.59% | $237.67K |
| Arrowhead Pharmaceuticals, Inc. | 4.41% | $228.01K |
| Alkermes Public Limited Company | 4.20% | $217.29K |
| Centessa Pharmaceuticals PLC | 3.95% | $204.43K |
| argenx SE | 3.88% | $200.90K |
| Ptc Therapeutics, Inc. | 3.69% | $191.15K |
| Neurocrine Biosciences, Inc. | 3.68% | $190.66K |
| Biogen Inc. | 3.67% | $190.04K |
| Scholar Rock Holding Corp | 3.67% | $189.94K |
| Praxis Precision Medicines Inc | 3.66% | $189.39K |
| Acadia Pharmaceuticals Inc. | 3.61% | $186.96K |
| Dianthus Therapeutics Inc | 3.39% | $175.42K |
| Catalyst Pharmaceuticals, Inc. | 3.29% | $170.13K |
| Denali Therapeutics Inc | 2.82% | $146.02K |
| Supernus Pharmaceuticals, Inc. | 2.78% | $144.00K |
| Edgewise Therapeutics Inc | 2.53% | $131.02K |
| Dyne Therapeutics, Inc | 2.36% | $122.25K |
| AxoGen, Inc. | 2.34% | $120.96K |
| Sarepta Therapeutics, Inc. | 2.21% | $114.42K |
| SK Biopharmaceuticals Co Ltd | 2.04% | $105.63K |
| H. Lundbeck A/s | 1.92% | $99.24K |
| Capricor Therapeutics Inc | 1.75% | $90.43K |
| Taysha Gene Therapies Inc | 1.53% | $79.04K |
| BioArctic AB | 1.37% | $71.05K |
| Biohaven Ltd | 1.30% | $67.28K |
| Neuren Pharmaceuticals Ltd | 1.06% | $54.70K |
| Rapport Therapeutics Inc | 1.03% | $53.34K |
| Dynavox Group AB | 0.94% | $48.45K |
| Bright Minds Biosciences Inc | 0.92% | $47.41K |
| Idorsia Ltd | 0.87% | $45.10K |
| Annexon Inc | 0.80% | $41.37K |
| Alto Neuroscience Inc | 0.78% | $40.31K |
| SanBio Company Limited | 0.75% | $38.84K |
| Integra Lifesciences Holdings Corporation | 0.75% | $38.73K |
| Medincell SA | 0.65% | $33.46K |
| LB Pharmaceuticals Inc | 0.63% | $32.85K |
| Brainsway Ltd | 0.60% | $30.95K |
| Ceribell Inc | 0.52% | $26.95K |
| Prothena Corporation PLC | 0.51% | $26.46K |
| Zylox-Tonbridge Medical Technology Co Ltd | 0.51% | $26.36K |
| Oncolys Biopharma Inc | 0.49% | $25.40K |
| Relmada Therapeutics Inc | 0.48% | $25.07K |
| Solid Biosciences Inc | 0.46% | $23.97K |
| MicroPort NeuroScientific Corp | 0.46% | $23.96K |
| Design Therapeutics Inc | 0.46% | $23.72K |
| Neuropace Inc | 0.46% | $23.57K |
| Regenxbio Inc | 0.44% | $22.71K |
| Benitec Biopharma Inc | 0.42% | $21.67K |
| MapLight Therapeutics Inc | 0.42% | $21.58K |
| Vanda Pharmaceuticals Inc. | 0.41% | $21.27K |
| Peijia Medical Limited | 0.40% | $20.68K |
| Newron Pharmaceuticals SpA | 0.35% | $18.14K |
| Neurogene Inc. | 0.34% | $17.69K |
| Ovid Therapeutics Inc. | 0.34% | $17.63K |
| Anavex Life Sciences Corp | 0.32% | $16.51K |
| Entrada Therapeutics Inc | 0.31% | $15.90K |
| Clearpoint Neuro Inc | 0.31% | $15.85K |
| Santhera Pharmaceuticals Holding AG | 0.28% | $14.29K |
| AC Immune SA | 0.20% | $10.15K |
| Alector Inc | 0.19% | $9.74K |
| Inhibikase Therapeutics Inc | 0.19% | $9.60K |
| Voyager Therapeutics Inc | 0.18% | $9.38K |
| Larimar Therapeutics Inc | 0.18% | $9.26K |
| Tonix Pharmaceuticals Holding Corp. | 0.17% | $8.90K |
| Myung In Pharm Co Ltd | 0.16% | $8.04K |
| Neumora Therapeutics Inc | 0.15% | $7.56K |
| Acumen Pharmaceuticals Inc | 0.12% | $6.11K |
| PepGen Inc | 0.11% | $5.50K |
| Cognition Therapeutics Inc | 0.11% | $5.47K |
| BrainAurora Medical Technology Ltd | 0.09% | $4.84K |
| Gain Therapeutics Inc | 0.07% | $3.87K |
| Filana Therapeutics, Inc | 0.07% | $3.56K |
| Sangamo Therapeutics, Inc. | 0.05% | $2.59K |
| BlackRock Funds III: BlackRock Cash Funds: Treasury; SL Agency Shares | 0.05% | $2.45K |
| Australian Dollar | 0.02% | $1.01K |
| Japanese Yen | 0.02% | $883 |
| Swiss Franc | 0.01% | $282 |
| Swedish Krone | 0.00% | $191 |
| Korean Won | 0.00% | $129 |
| Hong Kong Dollar | 0.00% | $99 |
| Euro | 0.00% | $75 |
| Danish Kroner | 0.00% | $70 |
IBRN overview: performance, fees, allocation and SEC filings